Bexagliflozin and Octreotide interaction
Bexagliflozin and Octreotide: the Octreotide prescribing label describes an interaction that usually calls for monitoring, a dose change, or spacing the doses.
Usually manageable with monitoring or a dose change. Tell your pharmacist you take both.
What the FDA labels say
From the Octreotide (Mycapssa) label · effective 2025-07-24
Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed ( 5.2 ).
Adjust antidiabetic treatment accordingly .
Insulin and Antidiabetic Drugs: patients receiving insulin or antidiabetic drugs agents may require dose adjustment ( 7 ).
Patients receiving insulin or antidiabetic drugs agents may require dose adjustment of these therapeutic agents.
Insulin and Antidiabetic Drugs Clinical Impact: MYCAPSSA inhibits the secretion of insulin and glucagon.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.